Results 121 to 130 of about 21,074 (263)

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy? [PDF]

Curr Hypertens Rep
Kylies D, Dreher L, Wenzel UO.
europepmc   +1 more source

Effects of GLP‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review

The FEBS Journal, EarlyView.
This systematic review evaluated 17 studies (12 preclinical and five clinical) on GLP‐1 receptor agonists in type 2 diabetes, demonstrating effects on the gut microbiota and metabolic improvement. The studies showed an increase in Bacteroidetes, Lactobacillus, and Akkermansia, and a reduction in Firmicutes.
Ranicleide Santos Dantas, Lucas Vinícius Souza Santos, André Gustavo Carvalho de Oliveira, Marina dos Santos Barreto, Deise Maria Rego Rodrigues Silva, Pedro Henrique Macedo Moura, Eloia Emanuelly Dias Silva, Ronaldy Santana Santos, Lucas Alves da Mota Santana, Rajiv Gandhi Gopalsamy, Adriana Gibara Guimarães, Lysandro Pinto Borges   +11 more
wiley   +1 more source

From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Santulli G.
europepmc   +1 more source

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework. [PDF]

Obes Pillars
Simancas-Racines D, Campuzano-Donoso M, Rossetti G, Cobellis L, Pilone V, Fascì-Spurio F, Jima Gavilanes D, Soria C, Reytor-González C, Schiavo L.   +9 more
europepmc   +1 more source

Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis

Journal of Diabetes Investigation, EarlyView.
Liraglutide reverses hyperglycemia‐induced metabolic reprogramming in vascular smooth muscle cells, restoring mitochondrial function and AMPK/PGC‐1α signaling while suppressing mTOR activation and HIF‐1α accumulation. These changes attenuate extracellular matrix remodeling, reduce atherosclerotic plaque burden, and improve plaque stability in diabetic ...
Kun Zhu, Hanxiu Liu, Ni He, Haoyang Wang, Jing Liu, Qinhu Zhang, Zhongwei Liu   +6 more
wiley   +1 more source

Clinical and psychological effects of the JADEC Diabetes Card System assessed using the Problem Areas in Diabetes (PAID): A retrospective observational study

Journal of Diabetes Investigation, EarlyView.
A structured diabetes support program using a card‐based system was associated with reductions in diabetes‐related distress and improvements in glycemic control in real‐world clinical practice. These findings highlight the potential of shared‐care models to support patient‐centered diabetes management.
Yu Kouchi
wiley   +1 more source

Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance. [PDF]

Nutrients
Zambrano-Villacres R, Campuzano-Donoso M, Reytor-González C, Rossetti G, Cobellis L, Cobellis F, Pilone V, Simancas-Racines D, Schiavo L.   +8 more
europepmc   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, EarlyView.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source

Letter to the Editor: Endocrine determinants of diabetic ketoacidosis outcomes in type 2 diabetes and insights into Gymnema sylvestre actions. [PDF]

World J Exp Med
Milionis C, Zoumakis E, Ilias I.
europepmc   +1 more source